Nanobiotix Is A Clinical Biotechnology Company Based In Parisfrancefounded In 2003 And Publicly Listed On Euronext Paris And Nasdaqthe Company Focuses On Developing Physics Based Nanotherapeutics Aimed At Improving Cancer Treatment Outcomesparticularly By Enhancing Traditional Radiotherapy Methods The Company S Flagship Productnbtxr3Hensifyais A First In Class Radioenhancer Made From Hafnium Oxide Nanoparticlesit Is Designed To Increase Radiation Dose Absorption In Tumor Cells While Minimizing Damage To Healthy Tissuesnbtxr3 Is Marketed In Europe For Soft Tissue Sarcoma And Is Being Evaluated In Clinical Trials For Various Cancersincluding Head And Necklungand Pancreatic Cancers Nanobiotix Collaborates With Major Institutions And Has A Global Licensing Agreement With Janssen Pharmaceutica Nv For The Co Development Of Nbtxr3The Company Targets Healthcare Providers And Patientsparticularly Those With Limited Treatment Optionsand Operates In The Usspainand Germanywith A Mission To Enhance Life Expectancy And Quality For Cancer Patients Worldwide
| Company Name | Nanobiotix |
| Country |
France
|
| Address | N/A |
| Telephone | N/A |
| N/A |
United States